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diovascular diseases (log-OR  0.7488, S.E.  0.0912).
The overdispersion parameters for the NB model and the
two-part NB model were 0.3929 and 1.3796 respec-
tively, indicating the necessity of applying a two-part
model. CONCLUSION: Our data support the hypothesis
that there is individual heterogeneity for risk of hospital-
ization and a “healthy” sub-population of patients with
Type 2 diabetes. Consequently we recommend applica-
tion of two-part models that first predicts the risk of any
hospitalization for each individual in the population and
then predicts the likely number of hospitalizations sepa-
rately for high and low risk sub-populations.
DB2
AGGREGATION OF WILLINGNESS-TO-PAY 
MEASURED IN DECOMPOSED SCENARIOS
Klose T1, Zeitler HP2, Leidl R1
1Department of Health Economics, University of Ulm, Ulm, 
Germany; 2Department of General Medicine, University of 
Ulm, Ulm, Germany
OBJECTIVE: For cost-benefit analysis, health technolo-
gies with multiple effects should theoretically be valued
in a single scenario by a holistic willingness-to-pay (WTP)
measure. Recently, decomposed scenarios in which re-
spondents state their WTP for each individual effect were
used more often. Evidence can be found that the sum of
such decomposed WTPs overestimates the holistic WTP,
i.e. the holistic WTP is subadditive. No theoretically
founded and empirically validated aggregation function
for decomposed WTPs exists. Our aims were to derive
such an aggregation function and to test it empirically.
METHODS: Within an expected utility model, we identi-
fied risk aversion with respect to money and a positive
correlation of better health and marginal utility of money
as reasons for subadditivity. Under mutual utility inde-
pendence of health and money, we derived a theoretically
founded aggregation function covering these two im-
pacts. For an empirical application of this function, one
has to determine the utilities of the health states, of well-
defined states “rich&ill” and “poor&healthy”, and a
utility function over money—beside the decomposed
WTPs. In a contingent valuation study, we asked 92 pa-
tients with diabetes to state their WTP for reductions in
the risk of several diabetic complications in decomposed
and holistic scenarios. Utilities were measured by standard
gamble procedures. 46 patients (group 1) valued two com-
plications (diabetic retinopathy & neuropathy). The re-
maining 46 patients (group 2) valued also a third compli-
cation (diabetic foot). RESULTS: Subadditivity occurred
in both groups, but was not statistically significant. The
sum of decomposed WTPs overestimated holistic WTP by
8.3% in group 1 and 16% in group 2. Theoretically
founded aggregation underestimated holistic WTP by 2%
in group 1 and 1.2% in group 2. CONCLUSIONS: The
results of our pilot study suggest that the theoretically
founded aggregation function might overcome problems
of subadditivity, which can be economically relevant. Fur-
ther empirical testing of the approach is indicated.
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OBJECTIVE: To measure whether more rapid transition
toward insulin therapy in newly diagnosed Type II dia-
betic patients improves blood glucose control (BGC) and
reduces risk of diabetic related complications (DC).
METHODS: We used longitudinal data obtained from
IMS Mediplus UK to identify patients newly diagnosed
with Type II diabetes between November 1, 1993 and
October 31, 1994. Newly diagnosed was defined as no
prior diagnosis or use of anti-diabetic agents. Patient data
for five years included demography, laboratory values
(Hb1Ac), treatment, DC and comorbidities. Patients were
assigned to an initial treatment modality including diet
and exercise (DE), sulfonylureas (S), anti-hyperglycemics
(A), a combination (C), insulin (I), or insulin plus an oral
agent (IO). Each stepwise transition in treatment, Hb1Ac
readings and manifestations of DC were tracked for at
least five years. Generalized Estimating Equations (GEE)
estimated the expected reduction in Hb1Ac as patients
transitioned to insulin sooner while controlling for base-
line Hb1Ac and initial treatment assignment. Logistic re-
gression was used to estimate the change in risk of DC
associated with reductions in Hb1Ac and accelerated
transitioning toward insulin treatment. RESULTS: 2,137
patients were eligible for analysis. By initial treatment pa-
tients were allocated as follows: 1,894 (DE), 200 (S), 30
(A), 10 (C), 3 (I), and 0 (IO). Stepwise patients transitioned
toward insulin with 180 patients by year 5. A total of 49
patients (2.3%) had at least one DC after controlling for
baseline. Hb1Ac was reduced by 0.0037 (P  0.001) for
each day sooner the patient was transitioned toward insu-
lin therapy or a reduction of 1.0 in Hb1Ac (12.5%) can be
expected if transitioned within 270 days. Logistic results in-
dicated that transitioning toward insulin therapy by day
270 yields a reduction in risk of DC of 0.388% (P  0.01).
CONCLUSION: Sooner transitioning to insulin therapy




THE WILLINGNESS TO PAY FOR REDUCED 
URGE INCONTINENCE
Capri S1, Sormani MP2, Lavezzari M3, Velona T3
1University of Pavia, Milan, Italy; 2IST, Clinical Trials Unit, Genoa, 
Italy; 3Pharmacia & Upjohn, Milan, Italy
OBJECTIVE: To measure the willingness to pay (WTP)
for a reduction in the number of micturitions and urinary
